Entero Therapeutics, Inc. (GRDX) — Cash Flow-to-Debt Ratio
Entero Therapeutics, Inc. (GRDX) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of $-855.69K could theoretically repay 0% of its total liabilities ($45.81 Million) in one year. See how much free cash does Entero Therapeutics, Inc. generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Entero Therapeutics, Inc. Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Entero Therapeutics, Inc. across 12 annual periods. Also explore Entero Therapeutics, Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Entero Therapeutics, Inc. (2013–2024)
Year-by-year debt coverage analysis for Entero Therapeutics, Inc.. For market capitalisation and broader financial context, see how much is Entero Therapeutics, Inc. worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.33x | $-9.22 Million | $27.61 Million | ▲ +91.2% |
| 2023 | -3.77x | $-12.38 Million | $3.28 Million | ▲ +54.4% |
| 2022 | -8.28x | $-22.34 Million | $2.70 Million | ▼ -403.1% |
| 2021 | -1.65x | $-32.29 Million | $19.61 Million | ▼ -128.4% |
| 2020 | -0.72x | $-11.22 Million | $15.56 Million | ▲ +78.0% |
| 2019 | -3.27x | $-14.03 Million | $4.29 Million | ▲ +9.8% |
| 2018 | -3.63x | $-10.87 Million | $3.00 Million | ▼ -92.9% |
| 2017 | -1.88x | $-7.18 Million | $3.82 Million | ▼ -46.9% |
| 2016 | -1.28x | $-4.53 Million | $3.54 Million | ▼ -216.8% |
| 2015 | -0.40x | $-4.17 Million | $10.32 Million | ▼ -58.0% |
| 2014 | -0.26x | $-1.01 Million | $3.93 Million | ▼ -425190.2% |
| 2013 | 0.00x | $56.55 | $939.30K | — |